Category: Cardiovascular

BMS, Pfizer’s fast-growing Eliquis is about to steamroll market-leader warfarin: exec

Last year, Pfizer and Bristol-Myers Squibb’s Eliquis replaced Johnson & Johnson’s Xarelto as the leader of the novel oral anticoagulant class. And now, thanks to a $1.65 billion performance in the second quarter, it’s about to unseat an even bigger foe: warfarin, the drug that’s been a standard therapy for decades. https://www.fiercepharma.com/marketing/bms-pfizer-s-eliquis-will-unseat-market-leader-warfarin-coming-weeks-exec

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

(Reuters) – Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.
https://www.reuters.com/article/us-regeneron-pharms-sanofi-fr-cholestero/regeneron-sanofi-to-cut-price-of-heart-drug-in-express-scripts-deal-idUSKBN1I23FW

Oral anticoagulants still underutilized in AFib: study

Drugmakers have turned new generation anticoagulants into blockbusters as treatments for strokes and heart attacks, but one area of care where they have made little progress is for treating atrial fibrillation. Cardiology professionals in a new study says that is unfortunate for patients. http://www.fiercepharma.com/pharma/oral-anticoagulants-still-underutilized-afib-study